{
    "eid": "2-s2.0-85149989773",
    "title": "Incidence of Anti-Drug Antibodies to Monoclonal Antibodies in Asthma: A Systematic Review and Meta-Analysis",
    "cover-date": "2023-05-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Immunology and Allergy",
            "@code": "2723",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "Antidrug antibodies",
        "Asthma",
        "Biologics",
        "Immunogenicity",
        "mAbs"
    ],
    "authors": [
        "Ming Li Chen",
        "Tanawin Nopsopon",
        "Ayobami Akenroye"
    ],
    "citedby-count": 2,
    "ref-count": 68,
    "ref-list": [
        "Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma",
        "Anti-IL-5 therapies for asthma",
        "Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting \u03b22 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial",
        "Tezepelumab in adults with uncontrolled asthma",
        "Anti-interleukin-13 and anti-interleukin-4 agents versus placebo, anti-interleukin-5 or anti-immunoglobulin-E agents, for people with asthma",
        "Review of biologics in allergy and immunology",
        "The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis",
        "From the bench to clinical practice: understanding the challenges and uncertainties in immunogenicity testing for biopharmaceuticals",
        "Update on immunogenicity in severe asthma: experience with mepolizumab",
        "The molecular mechanisms that underlie the immune biology of anti-drug antibody formation following treatment with monoclonal antibodies",
        "Monoclonal antibodies for severe asthma: pharmacokinetic profiles",
        "Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry)",
        "Biologics-induced autoimmune diseases",
        "Autoimmune diseases induced by biological agents: a double-edged sword?",
        "The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: results from a multinational, real-world clinical practice, non-interventional study",
        "Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement",
        "RoB 2: a revised tool for assessing risk of bias in randomised trials",
        "ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions",
        "Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides\u2014harmonized terminology and tactical recommendations",
        "Meta-analysis in clinical trials",
        "Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions",
        "Metaprop: a Stata command to perform meta-analysis of binomial data",
        "Transformations related to the angular and the square root",
        "The inverse of the Freeman \u2013 Tukey double arcsine transformation",
        "Bias in meta-analysis detected by a simple, graphical test",
        "Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma",
        "Real-world effectiveness of benralizumab in severe eosinophilic asthma",
        "Omalizumab in patients with allergic (IgE-mediated) asthma and IgE/bodyweight combinations above those in the initially approved dosing table",
        "Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b2(2)-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial",
        "Oral glucocorticoid-sparing effect of benralizumab in severe asthma",
        "The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma",
        "SOURCE study group. Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study",
        "Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial",
        "Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma",
        "Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab",
        "Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma",
        "Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma",
        "One year treatment with omalizumab is effective and well tolerated in Japanese patients with moderate-to-severe persistent asthma",
        "Immunogenicity and safety of omalizumab in pre-filled syringes in patients with allergic (IgE-mediated) asthma",
        "Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials",
        "Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts",
        "Functionality and performance of an accessorized pre-filled syringe and an autoinjector for at-home administration of tezepelumab in patients with severe, uncontrolled asthma",
        "Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma",
        "Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma",
        "A randomized trial of benralizumab, an antiinterleukin 5 receptor \u03b1 monoclonal antibody, after acute asthma",
        "Integrated safety and efficacy among patients receiving benralizumab for up to 5 years",
        "Efficacy and safety of anti-interleukin-5 therapy in patients with asthma: a systematic review and meta-analysis",
        "Efficacy and safety of benralizumab for eosinophilic asthma: a systematic review and meta-analysis of randomized controlled trials",
        "Efficacy and safety of benralizumab in patients with eosinophilic asthma: a meta-analysis of randomized placebo-controlled trials",
        "The efficacy and safety of reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: a systematic review and meta-analysis",
        "Efficacy and safety of treatment with dupilumab for severe asthma: a systematic review of the EAACI guidelines\u2014recommendations on the use of biologicals in severe asthma",
        "Comparative efficacy and safety of tezepelumab and other biologics in patients with inadequately controlled asthma according to thresholds of type 2 inflammatory biomarkers: a systematic review and network meta-analysis",
        "Efficacy and safety of anti-interleukin-5 therapy in patients with asthma: a pairwise and Bayesian network meta-analysis",
        "Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: a Bayesian network meta-analysis",
        "Anti-drug antibodies of IL-23 inhibitors for psoriasis: a systematic review",
        "Pharmacokinetics of risankizumab in Asian healthy subjects and patients with moderate to severe plaque psoriasis, generalized pustular psoriasis, and erythrodermic psoriasis",
        "An observational, prospective study of monthly adalimumab therapy for disease maintenance in psoriasis patients: a possible new therapeutic option for good responders to the initial induction treatment",
        "Dose adjustment of biologic therapies for psoriasis in dermatological practice: a retrospective study",
        "Comparison of tightly controlled dose reduction of biologics with usual care for patients with psoriasis: a randomized clinical trial",
        "Dose tapering of biologics in patients with psoriasis: a scoping review",
        "Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis",
        "Extent and consequences of antibody formation against adalimumab in patients with psoriasis: one-year follow-up",
        "Long-term dose optimization of adalimumab via dose spacing in patients with psoriasis",
        "Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial",
        "Assessment of an accessorized pre-filled syringe for home-administered benralizumab in severe asthma",
        "Single-use autoinjector functionality and reliability for at-home administration of benralizumab for patients with severe asthma: GRECO trial results",
        "Benralizumab does not impair antibody response to seasonal influenza vaccination in adolescent and young adult patients with moderate to severe asthma: results from the phase IIIb ALIZE trial",
        "Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial"
    ],
    "affiliation": [
        {
            "affiliation-city": "Boston",
            "@id": "60016782",
            "affilname": "Brigham and Women's Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60016782",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Boston",
            "@id": "60032499",
            "affilname": "Harvard T.H. Chan School of Public Health",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60032499",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Taichung",
            "@id": "60027767",
            "affilname": "Chung Shan Medical University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60027767",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Baltimore",
            "@id": "60006183",
            "affilname": "Johns Hopkins Bloomberg School of Public Health",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60006183",
            "affiliation-country": "United States"
        }
    ],
    "funding": [
        "R00 MOSAIC",
        "National Institutes of Health",
        "National Institute on Minority Health and Health Disparities K99"
    ]
}